Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WP-0508ST Phase II/III clinical trial in diabetic macular edema
jRCT2080222093Phase 3
- Sponsor
- Wakamoto Pharmaceutical
- Start
- May 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of triamcinolone acetonide in diabetic macular edema (DME), nonproliferative diabetic retinopathy (NPDR) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Wakamoto Pharmaceutical.
02
Drugs
triamcinolone acetonide
03
Conditions
diabetic macular edema (DME)nonproliferative diabetic retinopathy (NPDR)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080222093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222093.